

Indoleamine 2,3-dioxygenase pathways of pathogenic in cancer

Cancer Immunology, Immunotherapy

63, 721-735

DOI: [10.1007/s00262-014-1549-4](https://doi.org/10.1007/s00262-014-1549-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
2	IDO2 in Immunomodulation and Autoimmune Disease. <i>Frontiers in Immunology</i> , 2014, 5, 585.	2.2	112
3	Indoleamine 2,3-Dioxygenase Inhibitors Isolated from the Sponge <i>Xestospongia vansoestii</i> : Structure Elucidation, Analogue Synthesis, and Biological Activity. <i>Organic Letters</i> , 2014, 16, 6480-6483.	2.4	21
4	The Immunotherapeutic Role of Regulatory T Cells in <i>Leishmania (Viannia) panamensis</i> Infection. <i>Journal of Immunology</i> , 2014, 193, 2961-2970.	0.4	35
5	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. <i>Blood</i> , 2015, 125, 3905-3916.	0.6	260
6	Inflammation and Suicidal Behavior. <i>Advances in Biological Psychiatry</i> , 2016, , 123-144.	0.2	3
7	Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests. <i>International Journal of Tryptophan Research</i> , 2015, 8, IJTR.S26862.	1.0	89
8	A High-Throughput Assay for Screening of Natural Products that Enhanced Tumoricidal Activity of NK Cells. <i>Biological Procedures Online</i> , 2015, 17, 12.	1.4	16
9	Targeting the indoleamine 2,3-dioxygenase pathway in cancer. , 2015, 3, 51.		280
10	Targeting the gastrointestinal tract to develop novel therapies for HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 381-386.	2.3	6
11	Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue. <i>Cancer</i> , 2015, 121, 2129-2136.	2.0	68
12	The immune system and gastrointestinal stromal tumor. <i>Current Opinion in Oncology</i> , 2015, 27, 338-342.	1.1	14
13	Catalytic Mechanism of Cofactor-Free Dioxygenases and How They Circumvent Spin-Forbidden Oxygenation of Their Substrates. <i>Journal of the American Chemical Society</i> , 2015, 137, 7474-7487.	6.6	70
14	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. <i>Cancer Letters</i> , 2015, 368, 246-251.	3.2	43
15	Intercellular Communication in Cancer. , 2015, , .		4
16	Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. <i>Hepatology</i> , 2015, 61, 1615-1626.	3.6	83
17	The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 16-18.	7.7	319
18	Recent advances in isolation, synthesis, and evaluation of bioactivities of bispyrroloquinone alkaloids of marine origin. <i>Chinese Journal of Natural Medicines</i> , 2015, 13, 561-577.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Genetic disorders coupled to ROS deficiency. <i>Redox Biology</i> , 2015, 6, 135-156.	3.9	130
20	Is tryptophan metabolism involved in sleep apnea-related cardiovascular co-morbidities and cancer progression?. <i>Medical Hypotheses</i> , 2015, 85, 415-423.	0.8	9
21	T cell metabolic fitness in antitumor immunity. <i>Trends in Immunology</i> , 2015, 36, 257-264.	2.9	237
22	Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9421-9437.	2.9	179
23	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	7.7	3,266
24	Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. <i>Oncolmmunology</i> , 2015, 4, e968480.	2.1	25
25	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015, 13, 412-424.	2.9	387
26	Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. <i>Oncolmmunology</i> , 2015, 4, e981457.	2.1	78
27	Toxicity of terflunomide in aryl hydrocarbon receptor deficient mice. <i>Biochemical Pharmacology</i> , 2015, 98, 484-492.	2.0	8
28	Cell-Cell Fusion, Chemotaxis and Metastasis. , 2015, , 227-254.		0
29	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 868-876.	3.4	358
30	Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 75407-75424.	0.8	66
31	Vascular Alterations in a Murine Model of Acute Graft-Versus-Host Disease Are Associated with Decreased Serum Levels of Adiponectin and an Increased Activity and Vascular Expression of Indoleamine 2,3-Dioxygenase. <i>Cell Transplantation</i> , 2016, 25, 2051-2062.	1.2	11
32	NK Cell-Dependent Growth Inhibition of Lewis Lung Cancer by Yu-Ping-Feng, an Ancient Chinese Herbal Formula. <i>Mediators of Inflammation</i> , 2016, 2016, 1-7.	1.4	21
33	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 21-30.	1.0	46
34	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
35	Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 2345-2354.	1.1	59
37	Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor Efficiency. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e397.	2.3	7

#	ARTICLE	IF	CITATIONS
38	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
39	IDO2 Modulates T Cell–Dependent Autoimmune Responses through a B Cell–Intrinsic Mechanism. <i>Journal of Immunology</i> , 2016, 196, 4487-4497.	0.4	56
40	Dendritic Cell–Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	3.2	295
41	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. <i>Journal of Neuroimmunology</i> , 2016, 297, 117-126.	1.1	21
42	Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. <i>British Journal of Cancer</i> , 2016, 115, 1087-1095.	2.9	52
43	1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4330-4333.	1.0	35
44	Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure. <i>Molecular Informatics</i> , 2016, 35, 449-459.	1.4	11
45	In the Wnt-er of life: Wnt signalling in melanoma and ageing. <i>British Journal of Cancer</i> , 2016, 115, 1273-1279.	2.9	54
46	Immunotherapy in Gastrointestinal Malignancies. , 2016, , 27-69.		0
47	IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. <i>Clinical Medicine Insights Pathology</i> , 2016, 9s1, CPath.S39930.	0.6	45
48	Challenges in vaccine therapy in hematological malignancies and strategies to overcome them. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1093-1104.	1.4	3
49	Obesity and colorectal cancer: molecular features of adipose tissue. <i>Journal of Translational Medicine</i> , 2016, 14, 21.	1.8	133
50	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
51	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
52	Exploring NAD ⁺ metabolism in host–pathogen interactions. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1225-1236.	2.4	53
53	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 797-804.	2.0	20
54	The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities. <i>Future Medicinal Chemistry</i> , 2016, 8, 39-54.	1.1	13
55	The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1830-1840.	1.5	108

#	ARTICLE	IF	CITATIONS
56	<i>In silico</i> -driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors. <i>MedChemComm</i> , 2016, 7, 409-419.	3.5	25
57	Combined <i>Toxoplasma gondii</i> seropositivity and high blood kynurenine – Linked with nonfatal suicidal self-directed violence in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2016, 72, 74-81.	1.5	29
58	Antitumor dendritic cell–based vaccines: lessons from 20 years of clinical trials and future perspectives. <i>Translational Research</i> , 2016, 168, 74-95.	2.2	116
59	Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. <i>Translational Research</i> , 2016, 167, 67-79.	2.2	79
60	Current status of immunotherapy for gastrointestinal stromal tumor. <i>Cancer Gene Therapy</i> , 2017, 24, 130-133.	2.2	40
61	Polyketides and Anthranilic Acid Possessing 6-Deoxy- β -D-glucopyranose from a <i>Streptomyces</i> Species. <i>Journal of Natural Products</i> , 2017, 80, 1378-1386.	1.5	17
62	Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?. <i>Journal of Oncological Science</i> , 2017, 3, 52-56.	0.1	88
63	Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry. <i>MedChemComm</i> , 2017, 8, 1378-1392.	3.5	33
64	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
65	Regulatory T cells in multiple sclerosis and myasthenia gravis. <i>Journal of Neuroinflammation</i> , 2017, 14, 117.	3.1	227
66	Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 215-226.	1.0	33
67	Simultaneous determination of tryptophan and 8 metabolites in human plasma by liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1054, 36-43.	1.2	55
68	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <i>International Immunopharmacology</i> , 2017, 46, 210-219.	1.7	102
69	Disturbed tryptophan metabolism correlating to progression and metastasis of esophageal squamous cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 781-787.	1.0	38
70	Systematic study of imidazoles inhibiting IDO1 via the integration of molecular mechanics and quantum mechanics calculations. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 152-170.	2.6	13
71	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. <i>Cancer Research</i> , 2017, 77, 1783-1812.	0.4	270
72	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1323-1332.	1.5	35
73	Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation. <i>Cell Transplantation</i> , 2017, 26, 1428-1440.	1.2	12

#	ARTICLE	IF	CITATIONS
74	Discovery of IDO1 Inhibitors: From Bench to Bedside. <i>Cancer Research</i> , 2017, 77, 6795-6811.	0.4	433
75	Migrating into the Tumor: a Roadmap for T Cells. <i>Trends in Cancer</i> , 2017, 3, 797-808.	3.8	230
76	Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. <i>Nature Communications</i> , 2017, 8, 1811.	5.8	360
77	Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1. <i>Nature Communications</i> , 2017, 8, 1693.	5.8	129
78	Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer. <i>Metabolomics</i> , 2017, 13, 1.	1.4	20
79	Inhibitors of the Kynurenine Pathway. <i>Topics in Medicinal Chemistry</i> , 2017, , 371-371.	0.4	2
80	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
81	A review of the immunomodulatory role of dietary tryptophan in livestock and poultry. <i>Amino Acids</i> , 2017, 49, 67-74.	1.2	40
82	Targeting immune checkpoints in malignant glioma. <i>Oncotarget</i> , 2017, 8, 7157-7174.	0.8	42
83	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	2.2	72
84	Metabolic Footprints and Molecular Subtypes in Breast Cancer. <i>Disease Markers</i> , 2017, 2017, 1-19.	0.6	52
85	Platform-independent gene expression signature differentiates sessile serrated adenomas/polyps and hyperplastic polyps of the colon. <i>BMC Medical Genomics</i> , 2017, 10, 81.	0.7	14
86	CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice. <i>Oncotarget</i> , 2017, 8, 57964-57980.	0.8	41
87	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. <i>Oncotarget</i> , 2017, 8, 71249-71284.	0.8	138
88	1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon- β by increasing the expression of IFN- β RI 2 , IRF-1 and FAS. <i>International Journal of Molecular Medicine</i> , 2017, 40, 576-582.	1.8	13
89	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	0.8	115
90	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
91	Promising therapeutics of gastrointestinal cancers in clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 524-533.	0.6	1

#	ARTICLE	IF	CITATIONS
92	Obesity and Cancer: Existing and New Hypotheses for a Causal Connection. <i>EBioMedicine</i> , 2018, 30, 14-28.	2.7	179
93	Changes in the pattern of cytokine production from peripheral blood mononuclear cells in patients with rheumatoid arthritis treated with infliximab and their relation to plasma arginase activity. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1907-1914.	0.9	3
94	Alterations on Cellular Redox States upon Infection and Implications for Host Cell Homeostasis. <i>Experientia Supplementum</i> (2012), 2018, 109, 197-220.	0.5	4
95	A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 651-657.	1.0	24
97	A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. <i>Journal of the American College of Surgeons</i> , 2018, 226, 596-603.	0.2	5
98	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive "Cold" Tumors "Hot". <i>Trends in Cancer</i> , 2018, 4, 38-58.	3.8	130
99	A single amino acid residue regulates the substrate affinity and specificity of indoleamine 2,3-dioxygenase. <i>Archives of Biochemistry and Biophysics</i> , 2018, 640, 1-9.	1.4	7
100	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
101	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 779-791.	0.5	53
102	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
103	A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. <i>Journal of Immunotherapy</i> , 2018, 41, 151-157.	1.2	9
104	Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival. <i>Journal of Investigative Dermatology</i> , 2018, 138, 679-687.	0.3	27
105	Role of immune microenvironment in gastrointestinal stromal tumours. <i>Histopathology</i> , 2018, 72, 405-413.	1.6	22
106	Immune correlates of clinical outcome in melanoma. <i>Immunology</i> , 2018, 153, 415-422.	2.0	9
107	Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 656-669.	2.6	47
108	Indoleamine 2, 3-dioxygenase regulation of immune response (Review). <i>Molecular Medicine Reports</i> , 2018, 17, 4867-4873.	1.1	79
109	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51
110	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0

#	ARTICLE	IF	CITATIONS
111	Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881533.	1.4	27
112	Immune Checkpoints and Innovative Therapies in Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 464.	1.3	70
113	Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma. <i>Cancer Science</i> , 2018, 109, 3726-3736.	1.7	29
114	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. <i>Current Molecular Medicine</i> , 2018, 17, 527-540.	0.6	20
115	Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1977.	2.2	123
116	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. <i>Cell</i> , 2018, 175, 442-457.e23.	13.5	198
117	Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 494.	1.3	43
118	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 370.	1.3	91
119	Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. <i>Journal of Controlled Release</i> , 2018, 289, 125-145.	4.8	31
120	Selecting immuno-oncology-based drug combinations – what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
121	Pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1015-1021.	1.4	18
122	Profiling targetable immune checkpoints in osteosarcoma. <i>Onc Immunology</i> , 2018, 7, e1475873.	2.1	26
123	Evaluation of melatonin and AFMK levels in women with breast cancer. <i>Endocrine</i> , 2018, 62, 242-249.	1.1	26
124	Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. <i>Journal of Immunology Research</i> , 2018, 1-10.	0.9	15
125	Cancer Metabolism: Current Understanding and Therapies. <i>Chemical Reviews</i> , 2018, 118, 6893-6923.	23.0	161
126	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
127	Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy. <i>Advanced Science</i> , 2018, 5, 1700891.	5.6	259
128	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. <i>Cell Death and Disease</i> , 2018, 9, 620.	2.7	90

#	ARTICLE	IF	CITATIONS
129	Targeting the IDO1 pathway in cancer: from bench to bedside. <i>Journal of Hematology and Oncology</i> , 2018, 11, 100.	6.9	277
130	The Aryl Hydrocarbon Receptor and Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 286.	2.2	102
131	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 54.	1.3	62
132	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 61-67.	0.7	78
133	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	1.1	12
134	Toward innovative combinational immunotherapy: A systems biology perspective. <i>Cancer Treatment Reviews</i> , 2018, 68, 1-8.	3.4	13
135	Gamma-delta ($\gamma\delta$) T cells: friend or foe in cancer development?. <i>Journal of Translational Medicine</i> , 2018, 16, 3.	1.8	211
136	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 166-181.	0.9	10
137	The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0202045.	1.1	40
138	Recent advances in small molecule based cancer immunotherapy. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 582-598.	2.6	74
139	Immunotherapy combinations emerging in non-small-cell lung cancer. <i>Immunotherapy</i> , 2018, 10, 627-629.	1.0	0
140	LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 24-30.	3.6	153
141	Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy. <i>International Journal of Cancer</i> , 2019, 144, 933-946.	2.3	67
142	Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111629.	2.6	27
143	Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. <i>MedChemComm</i> , 2019, 10, 1740-1754.	3.5	20
144	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage III breast cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 230-236.	2.9	14
145	Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1690.	2.2	71
146	Indoleamine 2,3-Dioxygenase Activation by Interferon Gamma in Vascular Endothelial Rat Cells Requires Noncanonical NF- κ B Signaling. <i>Transplantation Proceedings</i> , 2019, 51, 2141-2145.	0.3	9

#	ARTICLE	IF	CITATIONS
147	DosR antigen Rv1737c induces activation of macrophages dependent on the TLR2 pathway. Cellular Immunology, 2019, 344, 103947.	1.4	4
148	Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase. Journal of the American Chemical Society, 2019, 141, 18771-18779.	6.6	22
149	The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1135.	1.3	30
150	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	4.3	200
151	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58
152	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	1.7	149
153	The Endothelium During Allogeneic Stem Cell Transplantation. , 2019, , 401-414.		0
154	Multiple myeloma cell-derived IL-32 ^Δ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Letters, 2019, 446, 38-48.	3.2	39
155	Discovery of potent indoleamine 2,3-dioxygenase (IDO) inhibitor from alkaloids in Picrasma quassioides by virtual screening and in vitro evaluation. F ^Å -toteraP ^Å - ^Å ç, 2019, 133, 137-145.	1.1	12
156	IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. Cancer Research, 2019, 79, 1138-1150.	0.4	136
157	Control of the Antitumor Immune Response by Cancer Metabolism. Cells, 2019, 8, 104.	1.8	50
158	Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors. Molecules, 2019, 24, 1874.	1.7	18
159	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. Journal of Cancer, 2019, 10, 1764-1771.	1.2	11
160	Global serum metabolomics profiling of colorectal cancer (Review). Molecular and Clinical Oncology, 2019, 11, 3-14.	0.4	34
161	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1897-1905.	1.2	4
162	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chemical Society Reviews, 2019, 48, 3771-3810.	18.7	292
163	Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO-1) mRNA is over-expressed in the duodenal mucosa and is negatively correlated with serum tryptophan concentrations in dogs with protein-losing enteropathy. PLoS ONE, 2019, 14, e0218218.	1.1	8
164	Body Mass Index and Colorectal Cancer. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
165	Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 16978-16989.	1.2	12
166	Competition for nutrients and its role in controlling immune responses. <i>Nature Communications</i> , 2019, 10, 2123.	5.8	174
167	Translation of cancer immunotherapy from the bench to the bedside. <i>Advances in Cancer Research</i> , 2019, 143, 1-62.	1.9	28
168	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
169	Co-treatment with interferon- β and 1-methyl tryptophan ameliorates cardiac fibrosis through cardiac myofibroblasts apoptosis. <i>Molecular and Cellular Biochemistry</i> , 2019, 458, 197-205.	1.4	19
170	Arginine, histidine and tryptophan: A new hope for cancer immunotherapy. <i>PharmaNutrition</i> , 2019, 8, 100149.	0.8	14
171	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
172	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	2.2	177
173	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2019, 90, 300-313.	4.1	50
174	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	76
175	H2S suppresses indoleamine 2, 3-dioxygenase 1 and exhibits immunotherapeutic efficacy in murine hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 88.	3.5	19
176	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 379-401.	21.5	805
177	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2019, 12, 125.	6.9	116
178	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541989002.	0.8	33
179	Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. <i>Seminars in Immunopathology</i> , 2019, 41, 41-48.	2.8	198
180	Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma. <i>Experimental Eye Research</i> , 2019, 181, 112-119.	1.2	10
181	Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway's Metabolites in Humans with Prostate Cancer. <i>Journal of Proteome Research</i> , 2019, 18, 1532-1541.	1.8	27
182	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4

#	ARTICLE	IF	CITATIONS
183	Computer-aided drug design in new druggable targets for the next generation of immune oncology therapies. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1397.	6.2	6
184	LAI overexpression and correlation with advanced pathological grade and immune suppressive status in oral squamous cell carcinoma. Head and Neck, 2019, 41, 1080-1086.	0.9	21
185	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88
186	Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical Cancer Research, 2019, 25, 724-734.	3.2	48
187	The role of IDO, IL10, and TGFβ2 in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Journal of Medical Virology, 2019, 91, 265-271.	2.5	33
188	Cancer Metabolism. , 2020, , 127-138.e4.		3
189	Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. Investigational New Drugs, 2020, 38, 468-477.	1.2	17
190	Niosomes as efficient drug delivery modules for encapsulation of Toll-like receptor 7 agonists and IDO-inhibitor. Applied Surface Science, 2020, 505, 144078.	3.1	20
191	Bioactive lipids as modulators of immune check point inhibitors. Medical Hypotheses, 2020, 135, 109473.	0.8	10
192	Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy. Nanoscale, 2020, 12, 3317-3329.	2.8	30
193	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2020, 13, 262-274.	1.7	49
194	Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Urologic Clinics of North America, 2020, 47, 111-118.	0.8	8
195	Metabolomic profiling in neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28113.	0.8	5
196	Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis. Heliyon, 2020, 6, e04866.	1.4	10
197	The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059.	1.3	47
198	Developing immune-regulatory materials using immobilized monosaccharides with immune-instructive properties. Materials Today Bio, 2020, 8, 100080.	2.6	5
199	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 ⁺ and CD4 ⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
200	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1548-1554.	1.3	44

#	ARTICLE	IF	CITATIONS
201	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolimmunology</i> , 2020, 9, 1777625.	2.1	91
202	The Effect of IDO on Neural Progenitor Cell Survival Under Oxygen Glucose Deprivation. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 581861.	1.8	3
203	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. <i>Frontiers in Immunology</i> , 2020, 11, 578877.	2.2	76
204	Long Noncoding RNAs, New Critical Regulators in Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 550987.	1.3	39
205	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
206	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1197.	1.3	30
207	Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1633.	2.2	26
208	Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. <i>International Journal of Infectious Diseases</i> , 2020, 99, 441-448.	1.5	12
209	Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2020, 10, 572722.	1.3	35
210	Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 1861.	2.2	70
211	Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. <i>ACS Nano</i> , 2020, 14, 13343-13366.	7.3	91
212	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. <i>Cancers</i> , 2020, 12, 2334.	1.7	15
213	Oncology Therapeutics Targeting the Metabolism of Amino Acids. <i>Cells</i> , 2020, 9, 1904.	1.8	21
214	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5845.	1.8	51
215	Application of Anti-Inflammatory Agents in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2680.	1.0	12
216	Eosinophils in Eosinophilic Esophagitis: The Road to Fibrostenosis is Paved With Good Intentions. <i>Frontiers in Immunology</i> , 2020, 11, 603295.	2.2	16
217	Obesity, Inflammation, and Advanced Prostate Cancer. <i>Nutrition and Cancer</i> , 2021, 73, 2232-2248.	0.9	15
218	Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. <i>Journal of Cellular Physiology</i> , 2020, 235, 9080-9097.	2.0	19

#	ARTICLE	IF	CITATIONS
219	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP β . <i>Frontiers in Immunology</i> , 2020, 11, 657.	2.2	24
220	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
221	Characterization of a Myeloid Activation Signature That Correlates with Survival in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1431.	1.7	1
222	Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 968.	2.2	25
223	The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch. <i>Frontiers in Immunology</i> , 2020, 11, 313.	2.2	19
224	New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of IDO1 Structures. <i>ChemMedChem</i> , 2020, 15, 891-899.	1.6	11
225	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	1.1	13
226	TGF-beta: a master immune regulator. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 427-438.	1.5	101
227	Yeast as a Model to Understand Actin-Mediated Cellular Functions in Mammalsâ€”Illustrated with Four Actin Cytoskeleton Proteins. <i>Cells</i> , 2020, 9, 672.	1.8	10
228	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 451-464.	1.6	63
229	<p>Differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis<p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6093-6108.	1.0	15
230	Mechanism of indoleamine 2, 3â€”dioxygenase inhibiting cardiac allograft rejection in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3438-3448.	1.6	8
231	Immunotherapy for glioma: Current management and future application. <i>Cancer Letters</i> , 2020, 476, 1-12.	3.2	351
232	Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. <i>Frontiers in Immunology</i> , 2020, 11, 140.	2.2	69
233	Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells. <i>Cancers</i> , 2020, 12, 488.	1.7	14
234	Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1943-1953.	5.7	47
235	Cytokines as potential combination agents with PDâ€”1/PDâ€”L1 blockade for cancer treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5449-5460.	2.0	42
236	Cancer immunotherapy through the prism of adaptation: Will Achilles catch the tortoise?. <i>Medical Hypotheses</i> , 2020, 137, 109545.	0.8	0

#	ARTICLE	IF	CITATIONS
237	Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 877.	1.7	32
238	Mechanism of tumor cells escaping from immune surveillance of NK cells. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 187-198.	1.1	17
239	PCC0208009, an indirect IDO1 inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala. <i>Biochemical Pharmacology</i> , 2020, 177, 113926.	2.0	12
240	Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1663-1672.	2.0	10
241	Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659.	1.4	8
242	Soluble CD83 inhibits acute rejection by up regulating TGF- β 2 and IDO secretion in rat liver transplantation. <i>Transplant Immunology</i> , 2021, 64, 101351.	0.6	5
243	Hepatitis C virus associated hepatocellular carcinoma. <i>Advances in Cancer Research</i> , 2021, 149, 103-142.	1.9	18
244	Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications. <i>Pharmacological Research</i> , 2021, 163, 105297.	3.1	120
245	Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy <i>via</i> tumor microenvironment modulation. <i>Nanoscale Horizons</i> , 2021, 6, 120-131.	4.1	108
246	Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets. , 2021, 221, 107746.		34
247	Role of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu. <i>International Journal of Sports Medicine</i> , 2021, 42, 389-406.	0.8	9
248	The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification. <i>Clinical Cancer Research</i> , 2021, 27, 689-703.	3.2	113
249	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
250	Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1275, 339-356.	0.8	1
251	Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. <i>Neurosurgical Focus</i> , 2021, 50, E5.	1.0	20
252	Carbamate and <i>N</i> -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 389-396.	1.3	14
253	The Distinctive Serum Metabolomes of Gastric, Esophageal and Colorectal Cancers. <i>Cancers</i> , 2021, 13, 720.	1.7	13
254	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2957-2972.	5.7	34

#	ARTICLE	IF	CITATIONS
255	Methylene blue and ascorbate interfere with the accurate determination of the kinetic properties of IDO2. <i>FEBS Journal</i> , 2021, 288, 4892-4904.	2.2	6
256	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
257	A Supramolecular "Trident" for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100729.	7.8	29
258	NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. <i>Journal of Biomedical Science</i> , 2021, 28, 26.	2.6	62
259	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. <i>Cancers</i> , 2021, 13, 1674.	1.7	9
260	Tryptophan Metabolites at the Crossroad of Immune-Cell Interaction via the Aryl Hydrocarbon Receptor: Implications for Tumor Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4644.	1.8	25
261	Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 620361.	1.3	12
262	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
263	A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. <i>ChemMedChem</i> , 2021, 16, 2195-2205.	1.6	9
264	A follicular regulatory Innate Lymphoid Cell population impairs interactions between germinal center Tfh and B cells. <i>Communications Biology</i> , 2021, 4, 563.	2.0	16
265	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. <i>Clinical and Translational Oncology</i> , 2021, 23, 2237-2252.	1.2	7
266	Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression. <i>Cell Communication and Signaling</i> , 2021, 19, 50.	2.7	14
267	Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1365-1378.	5.7	38
268	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102192.	3.4	15
269	The therapeutic potential of diet on immune-related diseases: based on the regulation on tryptophan metabolism. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 8793-8811.	5.4	10
270	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	1.3	10
271	Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. <i>Journal of Nanobiotechnology</i> , 2021, 19, 182.	4.2	23
272	Means, Motive, and Opportunity: Do Non-Islet-Reactive Infiltrating T Cells Contribute to Autoimmunity in Type 1 Diabetes?. <i>Frontiers in Immunology</i> , 2021, 12, 683091.	2.2	4

#	ARTICLE	IF	CITATIONS
273	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
274	Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway. <i>Biomedicines</i> , 2021, 9, 734.	1.4	111
275	<i>Toxoplasma gondii</i> , Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior. <i>Frontiers in Psychiatry</i> , 2021, 12, 665682.	1.3	19
276	The efficacy of indoximod upon stimulation with pro-inflammatory cytokines in triple-negative breast cancer cells. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 554-561.	1.1	1
277	Immunogenic camptothecin nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. <i>Nature Nanotechnology</i> , 2021, 16, 1130-1140.	15.6	84
278	Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 202, 114147.	1.4	2
280	Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV. <i>Viruses</i> , 2021, 13, 1747.	1.5	6
281	SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128214.	1.0	4
282	Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation. <i>Frontiers in Immunology</i> , 2021, 12, 725204.	2.2	5
283	Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 52, 128373.	1.0	3
284	Tryptophan-derived serotonin-kynurenine balance in immune activation and intestinal inflammation. <i>FASEB Journal</i> , 2021, 35, e21888.	0.2	36
285	Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 49, 128314.	1.0	7
286	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 631-641.	0.8	7
287	Adipose-derived stem cells for wound healing and fibrosis. , 2022, , 225-255.		0
288	Overview of the Kynurenine Pathway of Tryptophan Metabolism. , 2015, , 3-9.		7
289	Role of Kynurenine Pathway in Gastrointestinal Diseases. , 2015, , 157-167.		2
290	Next Generation of Cancer Immunotherapy: Targeting the Cancer-Immunity Cycle with Nanotechnology. , 2020, , 191-253.		2
291	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1

#	ARTICLE	IF	CITATIONS
292	1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/ β -catenin and NF- κ B/p53 while Enhances Lymphocytes NF- κ B, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma. Scientific Reports, 2018, 8, 9869.	1.6	17
293	IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology, 2020, 3, 252.	2.0	26
294	T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress, 2018, 2, 200-212.	1.4	22
295	Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation. Oncotarget, 2017, 8, 40486-40500.	0.8	26
296	Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma. Oncotarget, 2019, 10, 4546-4555.	0.8	11
297	Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma. Oncotarget, 2016, 7, 14781-14790.	0.8	18
298	IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget, 2016, 7, 52900-52911.	0.8	34
299	Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 2019, 26, 3009-3025.	1.2	286
300	Indoleamine 2,3-Dioxygenase Is Dispensable for The Immunomodulatory Function of Stem Cells from Human Exfoliated Deciduous Teeth. Cell Journal, 2017, 18, 597-608.	0.2	8
301	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
302	Tumor immune response and immunotherapy in gastric cancer. Journal of Pathology and Translational Medicine, 2020, 54, 20-33.	0.4	59
303	Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls. Frontiers in Medicine, 2021, 8, 727412.	1.2	4
304	Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward. , 2021, 9, e003013.		20
305	Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy, 2021, 6, 362.	7.1	212
307	Identification of Human IDO1 Enzyme Activity by Using Genetically Encoded Nitrotyrosine. ChemBioChem, 2020, 21, 1593-1596.	1.3	5
308	Therapeutic potential of melatonin in colorectal cancer: Focus on lipid metabolism and gut microbiota. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166281.	1.8	12
309	Polymeric Nanoparticles as a Promising Drug Delivery Platform for the Efficacious Delivery of Toll-Like Receptor 7/8 Agonists and IDO-Inhibitor. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2022, 632, 127764.	2.3	4
310	Bioactive Lipid (BAL)-Based Therapeutic Approach to Cancer That Enhances Antitumor Action and Ameliorates Cytokine Release Syndrome of Immune Checkpoint Inhibitors. , 2020, , 207-235.		0

#	ARTICLE	IF	CITATIONS
311	Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 1768-75.	0.5	12
312	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12339.	1.8	23
313	Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17950-17968.	2.9	19
314	Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives. <i>Frontiers in Immunology</i> , 2022, 13, 807271.	2.2	39
315	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
316	miR-4759 suppresses breast cancer through immune checkpoint blockade. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 241-251.	1.9	5
317	Changing Metabolic Patterns along the Colorectal Adenoma-Carcinoma Sequence. <i>Journal of Clinical Medicine</i> , 2022, 11, 721.	1.0	9
318	Myeloid-Derived Suppressor Cells in Solid Tumors. <i>Cells</i> , 2022, 11, 310.	1.8	39
319	Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy. <i>Biomedicines</i> , 2022, 10, 240.	1.4	1
320	A review on the molecular mechanisms, the therapeutic treatment including the potential of herbs and natural products, and target prediction of obesity-associated colorectal cancer. <i>Pharmacological Research</i> , 2022, 175, 106031.	3.1	7
321	Kynurenine and Anthranilic Acid in the Peritoneum Correlate With the Stage of Gastric Cancer Disease. <i>International Journal of Tryptophan Research</i> , 2022, 15, 117864692110656.	1.0	4
322	The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. <i>Journal of Immunology</i> , 2022, 208, 571-581.	0.4	13
323	Increased Kynurenine Indicates a Fatal Course of COVID-19. <i>Antioxidants</i> , 2021, 10, 1960.	2.2	23
324	Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma. <i>BMC Cancer</i> , 2022, 22, 233.	1.1	9
325	Inhibitory effect of ascorbate on tryptophan 2,3-dioxygenase. <i>Journal of Biochemistry</i> , 2022, , .	0.9	5
326	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6001-6016.	2.9	8
327	Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. <i>ACS Nano</i> , 2022, 16, 5184-5232.	7.3	32
328	The immune microenvironment in gastric adenocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 451-467.	8.2	47

#	ARTICLE	IF	CITATIONS
329	Elucidation of natural compounds Gallic acid and Shikonin for the treatment of HNSC cancer by targeting immune suppressor and tumour progressor genes. <i>Vegetos</i> , 0, , 1.	0.8	1
330	Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma using RNA Sequencing Expression Data. <i>World Neurosurgery</i> , 2022, , .	0.7	4
331	Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188701.	3.3	12
332	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
333	Impact of IDO1 and IDO2 on the B Cell Immune Response. <i>Frontiers in Immunology</i> , 2022, 13, 886225.	2.2	9
359	Correlation between amino acid metabolism and self-renewal of cancer stem cells: Perspectives in cancer therapy. <i>World Journal of Stem Cells</i> , 2022, 14, 267-286.	1.3	4
360	Emerging treatment landscape of non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 717-734.	1.4	8
361	Current state and upcoming opportunities for immunoPET biomarkers in lung cancer. <i>Lung Cancer</i> , 2022, 169, 84-93.	0.9	3
362	Leucine-tRNA-synthetase-2-expressing B cells contribute to colorectal cancer immunoevasion. <i>Immunity</i> , 2022, 55, 1067-1081.e8.	6.6	21
363	Dendritic cell transfer for cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 33-64.	1.6	7
364	Novel LncRNA ZFH4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
365	Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. <i>Journal of Controlled Release</i> , 2022, 348, 893-910.	4.8	41
366	The metabolic addiction of cancer stem cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
367	MUC1-mediated Macrophage Activation Promotes Colitis-associated Colorectal Cancer via Activating the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 789-811.	2.3	5
368	Identify metabolism-related genes IDO1, ALDH2, NCOA2, SLC7A5, SLC3A2, LDHB, and HPRT1 as potential prognostic markers and correlate with immune infiltrates in head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
369	Discovery of the First Selective IDO2 Inhibitor As Novel Immunotherapeutic Avenues for Rheumatoid Arthritis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14348-14365.	2.9	4
370	GAS6 From CD200+ Adipose-Derived Stem Cells Mitigates Colonic Inflammation in a Macrophage-Dependent Manner. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 289-301.	0.6	6
371	Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211207.	0.6	11

#	ARTICLE	IF	CITATIONS
372	Obesity and correlation with cancer. , 2023, , 47-82.		0
373	Tyk2 is a tumor suppressor in colorectal cancer. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
374	Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	1
375	Genetic Influences in <sc>Cancer-Associated</sc> Myositis. <i>Arthritis and Rheumatology</i> , 2023, 75, 153-163.	2.9	5
376	Tumor microenvironment antigens. <i>Seminars in Immunopathology</i> , 2023, 45, 253-264.	2.8	21
377	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
378	Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	4
379	Immunohistochemical expression of CB1 receptors in the liver of patients with HBV related-HCC. <i>Arab Journal of Gastroenterology</i> , 2022, , .	0.4	0
380	YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	1
381	Recent Photosensitizer Developments, Delivery Strategies and Combination-based Approaches for Photodynamic Therapy^{â€}. <i>Photochemistry and Photobiology</i> , 2023, 99, 469-497.	1.3	6
382	X-ray Emission Spectroscopy of Single Protein Crystals Yields Insights into Heme Enzyme Intermediates. <i>Journal of Physical Chemistry Letters</i> , 2023, 14, 41-48.	2.1	3
383	Self-oriented central-tumor delivery of legumain-cleavable vehicles governed by circulating monocyte/macrophage for precise tumor enrichment and immune activation. <i>Nano Research</i> , 2023, 16, 5189-5205.	5.8	2
384	Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer. <i>Cancers</i> , 2022, 14, 6131.	1.7	9
385	The Role of Hydrogen Sulfide in the Development and Progression of Lung Cancer. <i>Molecules</i> , 2022, 27, 9005.	1.7	4
386	Targeting Breast Cancer Stem Cells. <i>International Journal of Biological Sciences</i> , 2023, 19, 552-570.	2.6	18
387	Novel insight into metabolic reprogramming in cancer radioresistance: A promising therapeutic target in radiotherapy. <i>International Journal of Biological Sciences</i> , 2023, 19, 811-828.	2.6	4
388	Indoleamine 2,3-Dioxygenase (IDO) and Cancerous Cells. , 2023, , 1-23.		0
389	Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. <i>Molecular Cancer</i> , 2023, 22, .	7.9	14

#	ARTICLE	IF	CITATIONS
390	Hydrogen sulfide and its donors: Novel antitumor and antimetastatic agents for liver cancer. <i>Cellular Signalling</i> , 2023, 106, 110628.	1.7	3
392	Unwinding the modalities of necrosome activation and necroptosis machinery in neurological diseases. <i>Ageing Research Reviews</i> , 2023, 86, 101855.	5.0	6
393	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
394	Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2176-2187.	5.7	17
395	High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
396	Oral administration of nanoformulated indoximod ameliorates ulcerative colitis by promoting mitochondrial function and mucosal healing. <i>International Journal of Pharmaceutics</i> , 2023, 637, 122813.	2.6	5
397	Recent advances in the role of endogenous hydrogen sulphide in cancer cells. <i>Cell Proliferation</i> , 2023, 56, .	2.4	3
398	Nrf2 in TIME: The Emerging Role of Nuclear Factor Erythroid 2-Related Factor 2 in the Tumor Immune Microenvironment. <i>Molecules and Cells</i> , 2023, 46, 142-152.	1.0	5
399	Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
400	SLC14A1 is a new biomarker in renal cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	1
401	Necroptosis-related lncRNAs: establishment of a gene module and distinction between the cold and hot tumors in glioma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
410	Indoleamine 2,3-dioxygenase. , 2024, , 485-519.		0
414	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. <i>3 Biotech</i> , 2023, 13, .	1.1	0
419	Molecular biomarkers in pancreatic ductal adenocarcinoma. , 2024, , 151-173.		0
420	Recent advances in light-triggered cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2024, 12, 2650-2669.	2.9	0